Things have been way too quiet and the stock is getting crushed (my guess by impatient traders) since there has been a void of news. I have no contact with the company but I believe they are still waiting on FDA approval of the Phase 2b protocol, though I believe the CRO that they contracted with is ready to start when approval is given. Based on past press releases, I think the trial is scheduled to begin in the third quarter, so I hope we hear news from the FDA soon. While NTRP is as speculative as you can get, I think Bryostatin is one of the most promising AD drugs to be tested. You can read on the BRNI website about the 6 years of various testing they did and how the drug worked in multiple models to reduce AD proteins, amyloid plaque deposits, and restored memory. Gotta hold this for the long term.